Silo Pharma Teams Up With Allucent To Support Planned FDA Investigational New Drug Filing For SPC-15 Targeting PTSD

Silo Pharma, Inc., a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, has announced that it has selected Allucent, a global full-service clinical research organization, to assist with the final preparations and planned submission of its investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA). The IND will support a Phase 1 clinical trial of Silo’s intranasal prophylactic SPC-15 for the treatment of post-traumatic stress disorder (PTSD). The company currently plans to submit the IND in 2026 and, upon FDA approval, initiate its first-in-human trial for SPC-15.

Silo’s CEO, Eric Weisblum, stated that partnering with Allucent represents a key step toward bringing the company’s novel PTSD therapeutic into clinical development. He noted that Allucent’s expertise will help ensure that the IND provides a robust rationale for clinical testing. The initial Phase 1 trial will focus on dose-ranging studies to assess the pharmacokinetics and safety profile of SPC-15, and Silo anticipates favorable preclinical data in these areas that will satisfy FDA requirements for clinical trials.

The company expects to receive results from an IND-enabling toxicology and toxicokinetic study conducted under Good Laboratory Practice (GLP) standards, as well as data from a drug-device study evaluating the intranasal spray system designed specifically for SPC-15 delivery, in early 2026. Silo intends to pursue the FDA’s 505(b)(2) regulatory pathway, which can accelerate clinical development, for its SPC-15 program.